Cytokinetics Q1 Myqorzo Revenue of $19.4M Annualizes to ~$78M, Below Base Case Expectations

What happened

Cytokinetics reported Q1 2026 earnings that matched estimates, with revenue of $19.4M beating on the back of the Myqorzo launch for obstructive HCM. While the first commercial revenue marks a milestone, the quarterly figure annualizes to roughly $78M, trailing the $120M base-case projection for full-year 2026 from the latest DeepValue report. The report had flagged a potential sell rating, citing entrenched competition from Bristol Myers Squibb’s Camzyos and a leveraged balance sheet, with a bear-case value of $40 if launch sales failed to meet expectations. The early revenue data point, though positive, does not yet refute the bear case and suggests the ramp may be slower than the optimistic scenarios. Investors now await concrete launch metrics and the critical ACACIA-HCM nHCM data in Q2 2026 to gauge the true trajectory.

Implication

Over the next 12 months, the investment thesis hinges on Myqorzo’s ability to accelerate from this early launch base and the success of ACACIA-HCM in Q2 2026. A sustained sub-$120M 2026 revenue run-rate would reinforce the bear case and risk a de-rating toward the $40 downside scenario, while strong uptake and positive nHCM data could support the bull case. The current valuation ($63) offers limited margin of safety given negative equity and cash burn; investors should demand clear evidence of above-consensus execution before adding exposure.

Thesis delta

Early Myqorzo launch revenue of $19.4M in Q1 2026 annualizes to ~$78M, trailing the DeepValue base case of ~$120M for full year 2026. This slightly negative data point increases the probability of the bear case ($40) and reinforces the cautious stance, though one quarter does not define the trend. The thesis remains contingent on accelerating sales and positive ACACIA-HCM data in the coming quarters.